Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?

Nov 12, 2015 · 5m 8s
Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?
Description

Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including...

show more
Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.
show less
Information
Author cancerGRACE
Organization cancerGRACE
Website -
Tags

Looks like you don't have any active episode

Browse Spreaker Catalogue to discover great new content

Current

Podcast Cover

Looks like you don't have any episodes in your queue

Browse Spreaker Catalogue to discover great new content

Next Up

Episode Cover Episode Cover

It's so quiet here...

Time to discover new episodes!

Discover
Your Library
Search